BCL2 and plasma cell myeloma: Further research to prospectively identify patients with sensitive disease may improve the clinical utility of BH3-mimetics, a strategy which is most advanced in multiple myeloma, where t(11;14) and elevated BCL2 expression have been consistency associated with superior responses.